BRPI0708485A2 - métodos para distinguir isÈmeros usando espectrometria de massa - Google Patents
métodos para distinguir isÈmeros usando espectrometria de massa Download PDFInfo
- Publication number
- BRPI0708485A2 BRPI0708485A2 BRPI0708485-4A BRPI0708485A BRPI0708485A2 BR PI0708485 A2 BRPI0708485 A2 BR PI0708485A2 BR PI0708485 A BRPI0708485 A BR PI0708485A BR PI0708485 A2 BRPI0708485 A2 BR PI0708485A2
- Authority
- BR
- Brazil
- Prior art keywords
- adma
- sdma
- sample
- ions
- level
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 221
- 238000004949 mass spectrometry Methods 0.000 title claims abstract description 33
- YDGMGEXADBMOMJ-UHFFFAOYSA-N asymmetrical dimethylarginine Natural products CN(C)C(N)=NCCCC(N)C(O)=O YDGMGEXADBMOMJ-UHFFFAOYSA-N 0.000 claims abstract description 163
- NWGZOALPWZDXNG-LURJTMIESA-N (2s)-5-(diaminomethylideneamino)-2-(dimethylamino)pentanoic acid Chemical class CN(C)[C@H](C(O)=O)CCCNC(N)=N NWGZOALPWZDXNG-LURJTMIESA-N 0.000 claims abstract description 43
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 150000002500 ions Chemical class 0.000 claims description 210
- YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 claims description 177
- 239000000523 sample Substances 0.000 claims description 133
- HVPFXCBJHIIJGS-LURJTMIESA-N N(omega),N'(omega)-dimethyl-L-arginine Chemical compound CN\C(=N/C)NCCC[C@H](N)C(O)=O HVPFXCBJHIIJGS-LURJTMIESA-N 0.000 claims description 62
- 239000012472 biological sample Substances 0.000 claims description 58
- 230000002503 metabolic effect Effects 0.000 claims description 51
- 210000004027 cell Anatomy 0.000 claims description 48
- 150000001875 compounds Chemical class 0.000 claims description 45
- 208000019553 vascular disease Diseases 0.000 claims description 45
- 206010059245 Angiopathy Diseases 0.000 claims description 42
- 206010020772 Hypertension Diseases 0.000 claims description 37
- 239000004475 Arginine Substances 0.000 claims description 30
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 30
- 239000012634 fragment Substances 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 25
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 20
- 235000001014 amino acid Nutrition 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 241000124008 Mammalia Species 0.000 claims description 17
- 210000004369 blood Anatomy 0.000 claims description 17
- 239000008280 blood Substances 0.000 claims description 17
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 16
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 16
- 229960002173 citrulline Drugs 0.000 claims description 16
- 235000013477 citrulline Nutrition 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 201000011461 pre-eclampsia Diseases 0.000 claims description 16
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 15
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 15
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- -1 orthnitine Chemical compound 0.000 claims description 14
- 229940124597 therapeutic agent Drugs 0.000 claims description 14
- 239000013074 reference sample Substances 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 11
- 229960003624 creatine Drugs 0.000 claims description 10
- 239000006046 creatine Substances 0.000 claims description 10
- 150000007524 organic acids Chemical class 0.000 claims description 10
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 8
- 210000004381 amniotic fluid Anatomy 0.000 claims description 8
- 239000003529 anticholesteremic agent Substances 0.000 claims description 8
- 229940127226 anticholesterol agent Drugs 0.000 claims description 8
- 239000002220 antihypertensive agent Substances 0.000 claims description 8
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 210000003097 mucus Anatomy 0.000 claims description 8
- 210000002381 plasma Anatomy 0.000 claims description 8
- 210000003296 saliva Anatomy 0.000 claims description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims description 7
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- 201000006370 kidney failure Diseases 0.000 claims description 7
- 210000002751 lymph Anatomy 0.000 claims description 7
- 206010038464 renal hypertension Diseases 0.000 claims description 7
- 210000004243 sweat Anatomy 0.000 claims description 7
- 210000002700 urine Anatomy 0.000 claims description 7
- 229940030600 antihypertensive agent Drugs 0.000 claims description 6
- 210000001138 tear Anatomy 0.000 claims description 6
- 230000001419 dependent effect Effects 0.000 claims description 5
- 235000006408 oxalic acid Nutrition 0.000 claims description 5
- 210000001747 pupil Anatomy 0.000 claims description 5
- 229940124549 vasodilator Drugs 0.000 claims description 5
- 239000003071 vasodilator agent Substances 0.000 claims description 5
- 239000005541 ACE inhibitor Substances 0.000 claims description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 4
- 239000002160 alpha blocker Substances 0.000 claims description 4
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 claims description 4
- 239000002876 beta blocker Substances 0.000 claims description 4
- 229940097320 beta blocking agent Drugs 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 239000002934 diuretic Substances 0.000 claims description 4
- 229940030606 diuretics Drugs 0.000 claims description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 3
- 229910052805 deuterium Inorganic materials 0.000 claims description 3
- 210000002889 endothelial cell Anatomy 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 2
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 2
- 229940127088 antihypertensive drug Drugs 0.000 claims 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 238000004590 computer program Methods 0.000 claims 1
- 230000037323 metabolic rate Effects 0.000 claims 1
- 238000002552 multiple reaction monitoring Methods 0.000 description 17
- 230000007704 transition Effects 0.000 description 16
- 208000035475 disorder Diseases 0.000 description 15
- 208000030159 metabolic disease Diseases 0.000 description 14
- 230000000875 corresponding effect Effects 0.000 description 10
- 238000013467 fragmentation Methods 0.000 description 10
- 238000006062 fragmentation reaction Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 230000002526 effect on cardiovascular system Effects 0.000 description 9
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 239000012491 analyte Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000001819 mass spectrum Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 6
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 230000035935 pregnancy Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000001631 hypertensive effect Effects 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000003862 health status Effects 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 238000004611 spectroscopical analysis Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 230000008753 endothelial function Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 3
- 229960003104 ornithine Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001360 collision-induced dissociation Methods 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000002815 pulmonary hypertension Diseases 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011277 treatment modality Methods 0.000 description 2
- 108010087765 Antipain Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010070538 Gestational hypertension Diseases 0.000 description 1
- 201000005624 HELLP Syndrome Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000757232 Homo sapiens Protein arginine N-methyltransferase 2 Proteins 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 201000003099 Renovascular Hypertension Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000006208 butylation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004883 computer application Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000046485 human PRMT2 Human genes 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003225 hyperhomocysteinemia Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000004750 isotope dilution mass spectroscopy Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000005857 malignant hypertension Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77848306P | 2006-03-02 | 2006-03-02 | |
| US60/778,483 | 2006-03-02 | ||
| PCT/US2007/005279 WO2007103124A2 (en) | 2006-03-02 | 2007-03-02 | Methods for distinguishing isomers using mass spectrometry |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0708485A2 true BRPI0708485A2 (pt) | 2011-05-31 |
Family
ID=38475391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0708485-4A BRPI0708485A2 (pt) | 2006-03-02 | 2007-03-02 | métodos para distinguir isÈmeros usando espectrometria de massa |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20080073500A1 (https=) |
| EP (1) | EP1996923B1 (https=) |
| JP (1) | JP2009528544A (https=) |
| CN (1) | CN101438148B (https=) |
| AU (1) | AU2007224240B2 (https=) |
| BR (1) | BRPI0708485A2 (https=) |
| CA (1) | CA2644499A1 (https=) |
| DK (1) | DK1996923T3 (https=) |
| ES (1) | ES2392629T3 (https=) |
| WO (1) | WO2007103124A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005056408B4 (de) * | 2005-05-28 | 2007-05-31 | Esa Patentverwertungsagentur Sachsen-Anhalt Gmbh | Verfahren zur Bestimmung der Konzentration von asymmetrischem Dimethylarginin (ADMA) |
| JP2010540911A (ja) * | 2007-10-01 | 2010-12-24 | ディーエイチ テクノロジーズ デベロップメント プライベート リミテッド | アルコール消費の複合化した代謝産物の分析 |
| CN102421358A (zh) | 2009-03-10 | 2012-04-18 | 杜克大学 | 对冠心病和心血管事件风险的预测 |
| AU2015258285B2 (en) * | 2009-03-10 | 2017-09-07 | Duke University | Predicting coronary artery disease and risk of cardiovascular events |
| WO2010108180A2 (en) * | 2009-03-20 | 2010-09-23 | The Cleveland Clinic Foundation | Citrulline, a risk indicator for cardiovascular disease |
| EP2436025A1 (en) * | 2009-05-27 | 2012-04-04 | DH Technologies Development Pte. Ltd. | Linear ion trap for msms |
| JP5746154B2 (ja) * | 2009-05-28 | 2015-07-08 | ザ クリーブランド クリニック ファウンデーションＴｈｅ Ｃｌｅｖｅｌａｎｄ ＣｌｉｎｉｃＦｏｕｎｄａｔｉｏｎ | 疾患の診断および予測のためのトリメチルアミン含有化合物 |
| EP2438441B1 (en) * | 2009-06-02 | 2014-05-21 | BIOCRATES Life Sciences AG | New biomarkers for assessing kidney diseases |
| EP2443456A4 (en) * | 2009-06-15 | 2013-02-20 | Cleveland Clinic Foundation | METABOLITES OF ARGININE METHYLATES AS PREDICTORS OF CARDIOVASCULAR DISEASE RISK |
| CN102893156A (zh) * | 2009-12-21 | 2013-01-23 | 爱尔兰国立科克大学 | 子痫前期风险的检测 |
| US8703424B2 (en) * | 2010-03-22 | 2014-04-22 | Stemina Biomarker Discovery, Inc. | Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomics |
| CN107064330B (zh) * | 2010-12-28 | 2022-02-25 | 探索诊断投资公司 | 通过质谱法定量胰岛素 |
| CN102154444B (zh) * | 2010-12-30 | 2013-09-25 | 北京九强生物技术股份有限公司 | 测定不对称二甲基精氨酸浓度的方法及诊断试剂盒 |
| AU2012271718A1 (en) * | 2011-06-16 | 2014-01-09 | Baylor Research Institute | Analysis of total homocysteine and methylmalonic acid in plasma by LC-MS/MS from a plasma separator device (PSD) |
| WO2013140785A1 (ja) * | 2012-03-18 | 2013-09-26 | 国立大学法人九州大学 | 疾患サンプル分析装置、分析システム及び分析方法 |
| CN103207173B (zh) * | 2013-03-13 | 2015-06-17 | 北大工学院绍兴技术研究院 | 一种酶学检测方法 |
| WO2015044958A1 (en) | 2013-09-25 | 2015-04-02 | Council Of Scientific & Industrial Research | Quantitation of structural isomers using maldi ms/ms |
| JP6647224B2 (ja) | 2014-06-13 | 2020-02-14 | ディーエイチ テクノロジーズ デベロップメント プライベート リミテッド | 質量分析を用いる脂質の分析のための方法 |
| EP3259593B1 (en) * | 2015-02-20 | 2022-10-05 | IDEXX Laboratories, Inc. | Homogenous immunoassay with compensation for background signal |
| WO2016149220A1 (en) | 2015-03-13 | 2016-09-22 | Duke University | Compositions and methods for metabolic profiling in subjects with heart failure with preserved ejection fraction |
| CN104849298B (zh) * | 2015-05-26 | 2017-10-31 | 衢州普林千叶电子科技有限公司 | 一种用于核磁分析的样品检测分析仪和方法 |
| CN105628623B (zh) * | 2015-12-25 | 2018-08-24 | 北京市农林科学院 | 一种鉴别光学异构化合物旋光性的方法 |
| CN107764891B (zh) * | 2017-10-16 | 2020-03-13 | 杭州先导医药科技有限责任公司 | 一种恩替卡韦手性异构体的区分测定方法 |
| US10854438B2 (en) * | 2018-03-19 | 2020-12-01 | Agilent Technologies, Inc. | Inductively coupled plasma mass spectrometry (ICP-MS) with improved signal-to-noise and signal-to-background ratios |
| US11694886B2 (en) * | 2018-11-02 | 2023-07-04 | National University Corporation Kobe University | Analysis method, adsorption prevention agent, and analysis kit |
| US20220276263A1 (en) * | 2021-02-19 | 2022-09-01 | Idexx Laboratories, Inc. | Mass spectrometric analysis of biomarkers |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3055142B2 (ja) * | 1989-11-24 | 2000-06-26 | 株式会社島津製作所 | 質量分析方法 |
| JP2000111526A (ja) * | 1998-09-30 | 2000-04-21 | Hitachi Ltd | 質量分析計 |
| US20040191819A1 (en) * | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corporation | Expression profiles for breast cancer and methods of use |
| GB0308967D0 (en) * | 2003-04-17 | 2003-05-28 | Univ London | Screen for pre-eclampsia |
| DE102005056408B4 (de) * | 2005-05-28 | 2007-05-31 | Esa Patentverwertungsagentur Sachsen-Anhalt Gmbh | Verfahren zur Bestimmung der Konzentration von asymmetrischem Dimethylarginin (ADMA) |
-
2007
- 2007-03-02 CA CA002644499A patent/CA2644499A1/en not_active Abandoned
- 2007-03-02 CN CN200780016028.2A patent/CN101438148B/zh active Active
- 2007-03-02 JP JP2008557381A patent/JP2009528544A/ja active Pending
- 2007-03-02 AU AU2007224240A patent/AU2007224240B2/en active Active
- 2007-03-02 EP EP07752007A patent/EP1996923B1/en active Active
- 2007-03-02 BR BRPI0708485-4A patent/BRPI0708485A2/pt not_active IP Right Cessation
- 2007-03-02 US US11/681,744 patent/US20080073500A1/en not_active Abandoned
- 2007-03-02 DK DK07752007.0T patent/DK1996923T3/da active
- 2007-03-02 ES ES07752007T patent/ES2392629T3/es active Active
- 2007-03-02 WO PCT/US2007/005279 patent/WO2007103124A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN101438148B (zh) | 2014-01-22 |
| CA2644499A1 (en) | 2007-09-13 |
| WO2007103124A3 (en) | 2008-10-09 |
| AU2007224240B2 (en) | 2013-07-25 |
| ES2392629T3 (es) | 2012-12-12 |
| AU2007224240A1 (en) | 2007-09-13 |
| WO2007103124A2 (en) | 2007-09-13 |
| CN101438148A (zh) | 2009-05-20 |
| EP1996923A2 (en) | 2008-12-03 |
| US20080073500A1 (en) | 2008-03-27 |
| JP2009528544A (ja) | 2009-08-06 |
| EP1996923A4 (en) | 2010-04-07 |
| DK1996923T3 (da) | 2012-10-01 |
| EP1996923B1 (en) | 2012-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0708485A2 (pt) | métodos para distinguir isÈmeros usando espectrometria de massa | |
| ES2384288T3 (es) | Detección de succinilacetona | |
| Yin et al. | Effects of pre-analytical processes on blood samples used in metabolomics studies | |
| JP6021187B2 (ja) | 自閉症の代謝バイオマーカー | |
| CN112730692B (zh) | 用于预测胎膜早破的生物标记物和方法 | |
| Sun et al. | Novel SWATHTM technology for follicular fluid metabolomics in patients with endometriosis | |
| WO2024109767A1 (zh) | 基于粪便代谢物的阿尔兹海默症标志物及其应用 | |
| CN114252547A (zh) | 二甲基甘氨酸作为胎儿先天性心脏病血清标志物的应用 | |
| CN118090930A (zh) | 基于血液代谢物的阿尔茨海默症标志物及其应用 | |
| AU2014240270B2 (en) | Detecting succinylacetone | |
| CN118091146A (zh) | 基于血液代谢物的神经退行性疾病标志物及其应用 | |
| WO2024108604A1 (zh) | 基于血液代谢物的神经退行性疾病标志物及其应用 | |
| CN118671212A (zh) | 一组用于预测新型冠状病毒感染危重症患者的生物标志物 | |
| Gönel et al. | Determination of the Carnitine and Acylcarnitine Profile in Patients with Lipoid Proteinosis | |
| KR20140054850A (ko) | 질량분석기를 이용한 태아의 폐 성숙도 진단방법 | |
| Abbiss | Gas chromatography-mass spectrometry-based untargeted metabolomic analysis of organ tissue, plasma and urine samples from a Rat Model of polycystic kidney disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2366 DE 10-05-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |